ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2011
Atrial fibrillation: the cost of illness in Sweden.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04600713 (Physiotherapist Led Exercise Within Cardiac Rehabilitation and Inspiratory Muscle Training and Patients With Paroxysmal Atrial Fibrillation - a Randomized Controlled Trial), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Physiotherapist Led Exercise Within Cardiac Rehabilitation and Inspiratory Muscle Training and Patients With Paroxysmal Atrial Fibrillation - a Randomized Controlled Trial
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.PloS one · 2019Pooled it
- Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.Clinical drug investigation · 2014Trial
- Acute atrial fibrillation and flutter treated electively: rationale and design of the randomized controlled AFFELECT trial.European heart journal open · 2026Article
- Medical Costs and Productivity Losses of Atrial Fibrillation Among US Privately Insured Employees.JAMA network open · 2026Article
- Recent-onset atrial fibrillation: challenges and opportunities.European heart journal · 2026Review
- Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls.BMJ open · 2023Article
- One-year outcomes in cardiogenic shock triggered by supraventricular tachycardia: an analysis of the FRENSHOCK multicenter prospective registry.Frontiers in cardiovascular medicine · 2023Article
- Development and external validation of a prognostic model for occult atrial fibrillation in patients with ischemic stroke.Frontiers in neurology · 2022Article
- Large-scale screening studies for atrial fibrillation - is it worth the effort?Journal of internal medicine · 2021Review
- Cost of Illness for Five Major Foodborne Illnesses and Sequelae in Sweden.Applied health economics and health policy · 2018Article
- Cost of illness of atrial fibrillation: a nationwide study of societal impact.BMC health services research · 2017Article
- Economic impact of longer battery life of cardiac resynchronization therapy defibrillators in Sweden.ClinicoEconomics and outcomes research : CEOR · 2016Article
- Observational
- Uptake of atrial fibrillation screening aiming at stroke prevention: geo-mapping of target population and non-participation.BMC public health · 2013Article
- Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.The European journal of health economics : HEPAC : health economics in prevention and care · 2013Article
- Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation.PharmacoEconomics · 2013Review
- Article
- Article
- Analysis of the effectiveness and the cost of hospitalization of patients with atrial fibrillation.HippokratiaArticle
- The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation.Journal of atrial fibrillationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo provide an estimate of the annual cost of atrial fibrillation (AF) in Sweden.
methodsPrevalence-based cost analysis of AF in Sweden for 2007. Direct medical (hospitalizations, hospital outpatient care, primary health care, non-pharmacological interventions, pharmaceuticals, and anticoagulation monitoring) and non-medical (transportation associated with health care visits) costs of AF, direct costs of AF complications (stroke and heart failure), and indirect costs (production loss), were included. Data were based on Swedish registries, reports and databases, published literature, and an expert panel.
resultsThere were 100,557 individuals with AF as primary or secondary diagnosis that were either hospitalized or treated in hospital outpatient care in 2007. The total cost of AF was estimated at <euro>708 million. The major cost driver was the direct cost of complications (54%), followed by hospitalization due to AF including AF as secondary diagnosis (18%), and production loss (12%).
conclusionThis is a comprehensive, nation-based cost analysis of AF where relevant data were derived from national registries covering the entire Swedish population. The results showed that the annual cost of AF was high in comparison with other diseases, but likely to be underestimated as a conservative approach was applied in the analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.